Hans Lennart Rudolf Wigzell is Director at Sarepta Therapeutics, Inc. (SRPT). They have made 10 open-market trades across 1 company since 2017, most recently 2026-06-04.
CIK 0001492766
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SRPT | SELL | 2024-12-12 | 2024-12-16 | $124.84 | $1.3M | -2.9% | -4.6% | -19.0% |
| SRPT | SELL | 2024-03-08 | 2024-03-11 | $123.26 | $3.7M | +2.2% | +3.3% | +0.3% |
| SRPT | SELL | 2023-08-04 | 2023-08-08 | $106.72 | $1.6M | +7.9% | +17.6% | -22.8% |
| SRPT | SELL | 2021-03-08 | 2021-03-10 | $83.51 | $835K | -1.4% | -16.7% | -6.0% |
| SRPT | SELL | 2020-08-10 | 2020-08-11 | $159.00 | $3.2M | -10.0% | -19.4% | -20.4% |
| SRPT | SELL | 2020-05-20 | 2020-05-22 | $150.91 | $1.2M | -5.1% | +12.4% | -7.7% |
| SRPT | SELL | 2020-03-04 | 2020-03-06 | $116.89 | $584K | -24.0% | -6.7% | +33.8% |
| SRPT | SELL | 2019-05-23 | 2019-05-24 | $120.00 | $1.2M | +1.8% | +5.9% | -20.9% |
| SRPT | SELL | 2018-11-01 | 2018-11-02 | $140.50 | $1.9M | -23.7% | -10.8% | -4.9% |
| SRPT | SELL | 2017-11-30 | 2017-12-04 | $55.89 | $745K | -1.0% | +8.0% | +31.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.